PROGRAM DESCRIPTION:

This webinar series is about how companies work or want to work with universities to create value for both themselves and the universities. The ecology of innovation is undergoing a profound change where a collaborative set of activities need to effectively connect academic institutions with the business community. Universities are becoming key sources of discovery and are playing an ever increasing role in how industry innovates. Global competition, rising R&D costs and thus the need to get more products to the market sooner are some factors forcing companies to reach out to research universities for new ideas and capability. Licensing, corporate sponsored research, consulting engagements, venture capital investment, gifts, and employment are just some of the ways used to build strategic relationships between industry and universities, and are becoming a regular part of the developing open innovation environment.


_______________________


COST: Free, but registration required.

HOW TO PARTICIPATE?: This series is online. You need a computer with web access for the visual/audio. Q&A is conducted by a chat box to the speakers.

WHO SHOULD PARTICIPATE IN THE WEBINAR?: These webinars are open to anyone interested in how universities and industry can better collaborate to commercialize R&D. In particular, we invite Global 1000, VCs, angel investors and university officials.

_______________________


Martin Eglitis
(Senior Partnering Director, Teva Pharmaceutical Industries)

Bio

Martin Eglitis, Ph.D., is Senior Partnering Director, Teva Innovative Ventures, part of Teva Pharmaceutical Industries Ltd. He is responsible for the identification and evaluation of potential partnering opportunities in the entire western region of North America. In this role he is seeking early stage partnerships with both academic institutions and small biotechnology companies. Prior to joining Teva he was Associate Director of Licensing at Amgen Inc., where he was responsible for the identification, evaluation, and negotiation of in- and out-licensing opportunities across the drug development spectrum, from lead stage to registration. Among many licensing projects, Martin managed the partner interactions for the evaluation of an Amgen pain program, leading to a deal with J&J potentially valued in excess of $435 million. Before joining Amgen, he spent six years in Neuroscience and Cardiovascular licensing at Eli Lilly and Company. After a post-doctoral fellowship at the Roche Institute of Molecular Biology, he joined the National Institute of Heart, Lung and Blood at the NIH where he was involved in early efforts to develop transgenic mouse models and retroviral vectors for gene therapy. Dr. Eglitis was involved in one of the first gene therapy start-ups, Genetic Therapy Inc., from inception through its IPO and the first gene therapy clinical trials. Subsequently, Dr. Eglitis utilized his expertise in retroviral vectors to study adult CNS stem cells as a therapeutic avenue at the National Institutes of Mental Health and Neurological Disease and Stroke. Dr. Eglitis obtained his baccalaureate in Biology and Ph.D. in Anatomy and Developmental Biology from the University of Virginia.

_______________________


Shekar Rao
(Worldwide Manager, Texas Instruments Incorporated, Medical Electronics Solutions)

Bio

Shekar Rao is the worldwide manager for medical electronics and healthcare solutions at Texas Instruments in Dallas, Texas. He is responsible for identifying, evaluating and funding University R&D worldwide in Medical Electronics. This includes matching Clinical Needs and Medical System Innovation with TI’s current semiconductor component offering and future technology needs in the areas of Imaging, Implantable Devices, Patient Monitoring and Connected Health and Healthcare IT. Earlier he played a key role in five start-ups over the last ten years; served as founder, president, and chief executive officer for three of the five, including one in the area of Pharma-Healthcare. He possesses over 30 years of worldwide experience in product development, P&L, operations, business strategy, marketing, sales, and consulting within start-up as well as large companies such Texas Instruments, NEC Electronics and LSI Logic. He has a track record in developing and implementing multi-product and multi-market business strategies. Mr. Rao is highly knowledgeable in anti-trust issues, intellectual property protection, patents and the promotion of industry-wide interoperability standards and collaborations. He has a deep understanding of issues and opportunities in industries as diverse as semiconductor, life sciences, healthcare, networking hardware, software, IT, knowledge management and workflow automation. Mr. Rao has a BTech (BSEE) with thesis in Biomedical Engineering from IIT-Delhi, a Post Graduate Diploma (MBA) in International Trade from Indian Institute of Foreign Trade.

_______________________


Robert R. Gruetzmacher
(Director of Technology Commercialization, DuPont's Center for Collaborative Research and Education)

Bio

Dr. Gruetzmacher is the Director of Technology Commercialization in DuPont's Center for Collaborative Research and Education. During his career with DuPont, his responsibilities have included research, development, manufacturing, and marketing in the photopolymer imaging products and medical diagnostic businesses. He managed DuPont’s infectious disease diagnostics research group in Boston, co-managed a food quality assurance business venture, and helped lead development of DuPont's technology transfer group and intellectual assets business.

In his current role his responsibilities include managing the unrestricted grants program, leading DuPont’s efforts to find appropriate university partners for sponsored and collaborative research, negotiating agreements and seeks new business opportunities with the academic setting including startups, and advises company-wide on licensing-related matters. Most recently, he has been asked to take a lead in facilitating corporate-wide implementation of an “open innovation” R&D model.

Dr. Gruetzmacher holds a Ph.D. from Case Western Reserve University, and was the recipient of a National Institutes of Health Postdoctoral Fellowship. He has served as a trustee of the Licensing Executives Society and participates in several international forums dealing with topics such as university/company transactions, knowledge management, and the management and valuation of intellectual assets. He has authored publications and is invited frequently to gives talks on these topics. He is a certified licensing Professional and a member of the Licensing Executives Society, the American Chemical Society, the Association of University Technology Managers, and the American Association for the Advancement of Science. He is on the industrial advisory boards of the Larta Institute in Los Angeles, the Larta/USDA Commercialization Assistance Program and the Department of Macromolecular Science and Engineering at Case Western Reserve University. He was recently elected to the University-Industry Demonstration Partnership (UIDP) board of directors.

_______________________


Val R. Livada
(Senior Lecturer, Sloan School of Business at MIT; Founder Weybridge Partners)

Bio

Val Livada founded Weybridge Partners in 1996 as a network of formal and informal associations of practitioners and organizations focused on the successful commercialization of technology. The network includes business and technology consultants, venture capitalists, academics, entrepreneurs, lawyers, etc in the US and abroad.

Val brings 30 years of consulting experience to his clients. He was a Director at Braxton Associates, an international strategy planning consulting firm, and a Vice President at Pugh-Roberts Associates, a technology management firm established by Prof. Ed Roberts from MIT. Prior to establishing Weybridge Partners, he was the leading practitioner in the area of innovation management for the PA Consulting Group. During his career, Dr. Livada has combined expertise in the areas of strategic planning and organizational dynamics, with a detailed knowledge in the areas of innovation, product development, and R&D management.

Through the years, clients have included Fortune 500-type companies such as: GM, Eli Lilly, Nokia, Hitachi and has recently founded an East Coast corporate venture capital network. Val sits on the Board of Directors for Monarch Antenna, a Delphi Automotive spinout, and Polynova Composites. He is an business advisor to Liquid Bits a 3D animation start-up, Vanguard Solar, a thin film photovoltaic company, LuminZ an MIT spin out in LED lighting, Porticus a voice printing company, and Rapport Inc. a multicore chip company in CA. In addition, he consults to another dozen emerging companies.

Dr. Livada is also active in efforts to stimulate activities between US and European/Far Eastern organizations. In Europe Val has worked with many firms in the UK, Switzerland, Germany and Scandinavia. He has been instrumental in establishing US operations for several established and emerging European companies, including Nokia Research and Pro2Kem. In the Far East, traditionally strong ties to South Korea, Japan and Taiwan are now being expanded into China.

Val received his undergraduate degree from MIT and his MA/ PhD from Tufts University. Currently he is Senior Lecturer, on Corporate Entrepreneurship, at the Sloan School of Business at MIT where he also served as Reaserch Affiliate and Guest Lecturer for the last 15 years. At MIT, Val is leading a joint research project, with the Wharton Business School, on Corporate Venture Capital, is a Catalyst at the Deshpande Center, and a consultant to the Cambridge University/MIT Institute on various aspects of Innovation and Corporate/University partnerships.